Connect with us

Hi, what are you looking for?

Jewish Business News


Teva and Active Biotech Announce CONCERTO trial of Laquinimod trial fails

The CONCERTO trial of laquinimod in patients with relapsing-remitting multiple sclerosis did not meet its primary endpoint.


 Teva Pharmaceutical Industries Ltd. and its partner Active Biotech reported on Friday that the CONCERTO trial of its ethical drug laquinimod in patients with relapsing-remitting multiple sclerosis (RRMS) had not met its primary endpoint. This was the result of a trial of laquinimod (0.6 mg/daily capsules) versus a placebo to evaluate the time to Confirmed Disability Progression (CDP) after at least 3 months.Laquinimod is a once-daily oral, investigational, selective aryl hydrocarbon receptor (AhR) activator targeting neurodegeneration and inflammation with a novel mechanism of action being developed for the treatment of RRMS, primary-progressive MS (PPMS), and Huntington disease.Teva’s share price rose 0.9% on Friday. In the past year, Teva has fallen 43%, and its market cap has shrunk to $31.7 billion.

Earlier this year, Teva and Active Biotech announced that they were ceasing to give high doses of laquinimod in two studies of multiple sclerosis following non-fatal cardiac events reported in eight patients.

“We have learned a great deal from the CONCERTO trial and we will continue our analysis of the data,” said Teva president of Global R&D and chief scientific officer Michael Hayden. “Although we are disappointed by not meeting the primary endpoint, we did see positive results on a number of secondary and exploratory endpoints which fuels our belief in the potential of laquinimod as a possible treatment for neurodegenerative diseases. While we have no current plans to further pursue laquinimod in RRMS, we are continuing to study it in two other trials.”

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at
Thank you.

Teva continues to evaluate the potential of laquinimod in primary progressive MS (PPMS) and Huntington disease (HD) with two other clinical trials unaffected by the results of the CONCERTO trial. Complete data from the CONCERTO trial will be published in a scientific journal and presented at a future medical meeting.



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.